Welcome to our dedicated page for Adlai Nortye news (Ticker: ANL), a resource for investors and traders seeking the latest updates and insights on Adlai Nortye stock.
Adlai Nortye Ltd. reports clinical-stage biotechnology developments for an oncology pipeline focused on RAS-targeting therapies and next-generation cancer immunotherapies. Company updates include clinical and research activity for AN9025, an oral pan-RAS(ON) inhibitor, AN4035, a CEACAM5-targeting antibody-drug conjugate with a pan-RAS(ON) inhibitor payload, AN8025, a tri-functional fusion protein, and AN4005, an oral small-molecule PD-L1 inhibitor.
Recurring news for ANL also covers scientific presentations, license agreements, private-placement financing, shareholder and governance matters, investor conference participation, and American depositary share capital-structure disclosures tied to the company’s foreign-issuer reporting profile.
Adlai Nortye (NASDAQ: ANL) announced that the first U.S. patient has been dosed in the intermittent weekly (QW) arm of its ongoing global Phase 1 trial of AN9025, a pan-RAS(ON) inhibitor for advanced or metastatic solid tumors with RAS mutations.
The first-in-human, multicenter, open-label study is evaluating safety, tolerability, pharmacokinetics and anti-tumor activity of AN9025. Both the once-daily (QD) and QW dose-escalation arms are now enrolling. Based on preclinical data, the company believes intermittent dosing may widen the therapeutic window, and it plans to share initial Phase 1 QD arm data in 1H27, with a potential early look at QW data.
The trial is being conducted as a multi-regional clinical trial in collaboration with Jiangsu Aosaikang Pharmaceutical (ASK Pharm), under a license agreement in which Adlai Nortye holds ex-China rights and ASK Pharm retains rights in mainland China, Hong Kong and Macao.
Adlai Nortye (NASDAQ: ANL), a clinical-stage biotechnology company developing innovative cancer therapies, announced the expansion of its Scientific Advisory Board with the appointments of leading medical oncologists Dr. David S. Hong and Dr. Piro Lito.
According to Adlai Nortye, the company’s pipeline is anchored by its RAS inhibitor programs, including AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting antibody-drug conjugate leveraging its RASiCA™ platform, along with tri-specific immuno-oncology candidate AN8025. Management stated that the newly formed SAB will play a critical role in shaping R&D strategy and clinical development priorities, with Dr. Hong and Dr. Lito expected to contribute complementary expertise in clinical development, translational oncology, RAS biology, and targeted therapeutic strategies.
Adlai Nortye (Nasdaq: ANL) entered a private placement expected to raise approximately $150.0 million of gross proceeds by selling 11,320,755 ADSs at $13.25 per ADS. The oversubscribed financing includes new and existing institutional investors and is expected to close on April 17, 2026, subject to customary conditions.
Joint placement agents include Leerink Partners, Cantor, Lucid Capital Markets, H.C. Wainwright & Co. and Jones. The company agreed to file a resale registration statement with the SEC.
Adlai Nortye (NASDAQ: ANL) announced dosing of the first U.S. patient in early February 2026 in its global Phase 1, first-in-human trial of AN9025, an oral pan-RAS (ON) inhibitor for advanced or metastatic solid tumors with RAS mutations.
The multicenter, open-label MRCT evaluates safety, tolerability, pharmacokinetics and anti-tumor activity; Adlai Nortye retains ex-China rights while ASK Pharm holds rights in mainland China, Hong Kong and Macao.
Adlai Nortye (Nasdaq: ANL) announced a private placement expected to raise approximately $140.0 million gross, selling 64,615,386 Class A ordinary shares (equivalent to 21,538,462 ADS) at $2.1667 per share (equivalent to $6.50 per ADS).
The placement was co-led by Cormorant Asset Management and Columbia Threadneedle Investments, includes about $55 million purchased by entities controlled by Chairman and CEO Yang Lu, and will be registered for resale with the SEC.
Adlai Nortye (NASDAQ: ANL) entered an exclusive license agreement with ASK Pharm for its pan‑RAS (ON) inhibitor AN9025 in mainland China, Hong Kong and Macao on Dec 29, 2025. ASK Pharm gains rights to develop, manufacture, and commercialize AN9025 in the Licensed Territory while Adlai Nortye retains worldwide rights elsewhere.
The deal includes up to RMB 1.6 billion (~USD 230 million) in total consideration, an upfront payment and near‑term milestones exceeding USD 20 million, plus tiered royalties in the high single‑digit to mid‑teens on net sales in the Licensed Territory.
Adlai Nortye (NASDAQ: ANL) said members of management will participate in two investor conferences: a Fireside Chat at the 8th Annual Evercore Healthcare Conference on Dec 2, 2025, 4:15–4:35 PM ET at Loews Coral Gables Hotel (Sevilla A, Track 2) and a virtual presentation plus 1-on-1 meetings at the 36th Oppenheimer Annual Healthcare Life Sciences Conference on Feb 25–26, 2026. The company is a clinical-stage biotech focused on cancer therapies.
Adlai Nortye (NASDAQ: ANL) will present preclinical data for AN4035 at the AACR-NCI-EORTC conference in Boston on October 25, 2025.
Key highlights: AN4035 showed strong intracellular payload retention with nanomolar-to-picomolar cytotoxicity in CEACAM5-positive/RAS-addicted cell lines, a potent bystander-killing effect, deep regressions in CEACAM5-positive/RAS-addicted CDX and PDX models with a 73% objective response rate (N=26), and a favorable preliminary toxicology profile in cynomolgus monkeys.
The program is a CEACAM5-targeting ADC delivering a proprietary pan-RAS(ON) inhibitor payload designed to limit systemic toxicity and broaden the therapeutic window. Oral presentation: October 25, 2025, 11:45 AM ET; Poster session: October 25, 2025, Poster C (LB-C001).
Adlai Nortye (NASDAQ: ANL) will deliver an oral presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, held October 22–26, 2025.
Presentation: “Discovery of AN4035: A novel CEACAM5-targeting antibody drug conjugate (ADC) armed with a proprietary pan-RAS(ON) inhibitor payload.”
Date & Time: Saturday, October 25, 2025, 11:45 AM–12:15 PM ET, Level 3 Ballroom AB, Hynes Convention Center. The company will release scientific rationale and data highlights after the abstract posts on October 22, 2025.
Adlai Nortye (NASDAQ: ANL), a clinical-stage biotech company, will present two groundbreaking research abstracts at the AACR Annual Meeting in Chicago (April 25-30, 2025). The presentations highlight their innovative cancer therapy developments:
1. AN8025: A first-in-class tri-specific therapy for next-generation cancer immunotherapy, presenting on April 28, 2025 (2:00-5:00 PM CT)
2. AN9025: An orally bioavailable pan-RAS(ON) inhibitor showing broad-spectrum anti-tumor activity, presenting on April 29, 2025 (9:00 AM-12:00 PM CT)
Dr. Archie Tse, Head of R&D, emphasized the company's achievements in developing their multi-specific immune-oncology platform and innovative small molecule pan-RAS(ON) inhibitors. The presentation materials will be available on Adlai Nortye's website following the conference.